

JAN 22 2021

A BILL FOR AN ACT

RELATING TO SCHEDULE I SUBSTANCES.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. Chapter 321, Hawaii Revised Statutes, is
2 amended by adding a new section to be appropriately designated
3 and to read as follows:

4 "§321- Designated treatment centers; psilocybin. (a)
5 The department shall establish designated treatment centers for
6 the therapeutic administration of psilocybin and psilocyn.

7 (b) The department shall adopt rules in accordance with
8 chapter 91 necessary to implement this section."

9 SECTION 2. Section 329-14, Hawaii Revised Statutes, is
10 amended by amending subsection (d) to read as follows:

11 "(d) Any material, compound, mixture, or preparation that
12 contains any quantity of the following hallucinogenic
13 substances, their salts, isomers, and salts of isomers, unless
14 specifically excepted, whenever the existence of these salts,
15 isomers, and salts of isomers is possible within the specific
16 chemical designation:

17 (1) Alpha-ethyltryptamine (AET);



- 1 (2) 2,5-dimethoxy-4-ethylamphetamine (DOET);
- 2 (3) 2,5-dimethoxyamphetamine (2,5-DMA);
- 3 (4) 3,4-methylenedioxy amphetamine;
- 4 (5) 3,4-methylenedioxymethamphetamine (MDMA);
- 5 (6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-
- 6 MDA);
- 7 (7) 3,4-methylenedioxy-N-ethylamphetamine (MDE);
- 8 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 9 (9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);
- 10 (10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
- 11 (11) 3,4,5-trimethoxy amphetamine;
- 12 (12) Bufotenine;
- 13 (13) 4-methoxyamphetamine (PMA);
- 14 (14) Diethyltryptamine;
- 15 (15) Dimethyltryptamine;
- 16 (16) 4-methyl-2,5-dimethoxy-amphetamine;
- 17 (17) Gamma hydroxybutyrate (GHB) (some other names include
- 18 gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-
- 19 hydroxybutanoic acid; sodium oxybate; sodium
- 20 oxybutyrate);
- 21 (18) Ibogaine;



- 1 (19) Lysergic acid diethylamide;
- 2 (20) Marijuana;
- 3 (21) Parahexyl;
- 4 (22) Mescaline;
- 5 (23) Peyote;
- 6 (24) N-ethyl-3-piperidyl benzilate;
- 7 (25) N-methyl-3-piperidyl benzilate;
- 8 ~~[(26) Psilocybin];~~
- 9 ~~[(27) Psilocyn];~~
- 10 ~~[(28)]~~ (26) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
- 11 ~~[(29)]~~ (27) Ethylamine analog of phencyclidine (PCE);
- 12 ~~[(30)]~~ (28) Pyrrolidine analog of phencyclidine (PCPy, PHP);
- 13 ~~[(31)]~~ (29) Thiophene analog of phencyclidine (TCPy; TCP);
- 14 ~~[(32)]~~ (30) Gamma-butyrolactone, including butyrolactone;
- 15 butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone
- 16 dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone;
- 17 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-
- 18 hydroxybutyric acid lactone; 3-hydroxybutyric acid
- 19 lactone and 4-hydroxybutanoic acid lactone with
- 20 Chemical Abstract Service number 96-48-0 when any such
- 21 substance is intended for human ingestion;



- 1 ~~[(33)]~~ (31) 1,4 butanediol, including butanediol; butane-
2 1,4-diol; 1,4- butylenes glycol; butylene glycol; 1,4-
3 dihydroxybutane; 1,4- tetramethylene glycol;
4 tetramethylene glycol; tetramethylene 1,4- diol with
5 Chemical Abstract Service number 110-63-4 when any
6 such substance is intended for human ingestion;
- 7 ~~[(34)]~~ (32) 2,5-dimethoxy-4-(n)-propylthiophenethylamine
8 (2C-T-7), its optical isomers, salts, and salts of
9 isomers;
- 10 ~~[(35)]~~ (33) N-benzylpiperazine (BZP; 1-benzylpiperazine) its
11 optical isomers, salts, and salts of isomers;
- 12 ~~[(36)]~~ (34) 1-(3-trifluoromethylphenyl)piperazine (TFMPP),
13 its optical isomers, salts, and salts of isomers;
- 14 ~~[(37)]~~ (35) Alpha-methyltryptamine (AMT), its isomers,
15 salts, and salts of isomers;
- 16 ~~[(38)]~~ (36) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-
17 DIPT), its isomers, salts, and salts of isomers;
- 18 ~~[(39)]~~ (37) Salvia divinorum;
- 19 ~~[(40)]~~ (38) Salvinorin A;
- 20 ~~[(41)]~~ (39) Divinorin A;



- 1 [~~42~~] (40) 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT)
2 (some trade or other names: 5-methoxy-3-[2-
3 (dimethylamino)ethyl]indole; 5-MeO-DMT);
- 4 [~~43~~] (41) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-
5 E);
- 6 [~~44~~] (42) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-
7 D);
- 8 [~~45~~] (43) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-
9 C);
- 10 [~~46~~] (44) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
- 11 [~~47~~] (45) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine
12 (2C-T-2);
- 13 [~~48~~] (46) 2-[4-(Isopropylthio)-2,5-
14 dimethoxyphenyl]ethanamine (2C-T-4);
- 15 [~~49~~] (47) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
- 16 [~~50~~] (48) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-
17 N);
- 18 [~~51~~] (49) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine
19 (2C-P);
- 20 [~~52~~] (50) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
21 methoxybenzyl)ethanamine, its optical, positional, and



1 geometric isomers, salts, and salts of isomers (Other
2 names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);
3 ~~[(53)]~~ (51) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-
4 methoxybenzyl)ethanamine, its optical, positional, and
5 geometric isomers, salts, and salts of isomers (Other
6 names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); and
7 ~~[(54)]~~ (52) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
8 methoxybenzyl)ethanamine, its optical, positional, and
9 geometric isomers, salts, and salts of isomers (Other
10 names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)."

11 SECTION 3. (a) The governor shall establish and convene a
12 psilocybin review panel to review and assess the effects of this
13 Act.

14 (b) The review panel shall consist of:

- 15 (1) The governor or the governor's designee, who shall
16 serve as the chairperson of the panel;
17 (2) The director of health or the director's designee;
18 (3) The director of public safety or the director's
19 designee;



S.B. NO. 739

Report Title:

Psilocybin; Psilocyn; Therapeutic Administration;
Decriminalization

Description:

Removes psilocybin and psilocyn from the list of Schedule I substances. Requires the Department of Health to establish designated treatment centers for the therapeutic administration of psilocybin and psilocyn. Establishes a review panel to review and assess the effects of this measure.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

